653. Myeloma: Therapy, excluding Transplantation: Novel Approaches

Monday, December 5, 2016: 2:45 PM-4:15 PM
Moderators:
Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca-IBSAL and Brendan M. Weiss, MD, Abramson Cancer Center and Perelman School of Medicine, University of Pennsylvania
 
973

Andrzej Jakubowiak, Jagoda Jasielec, Cara A. Rosenbaum, Craig E. Cole, et al.

Conclusions: The combination of SEL, CFZ, and DEX demonstrates encouraging activity and safety in heavily pretreated, mostly CFZ-refractory myeloma. In addition, with 64% PR or better for pts progressing on CFZ, these results provide early clinical evidence that selinexor has the ability to overcome CFZ resistance, warranting further investigation of this regimen in RRMM.

974

Alfred L. Garfall, Edward A Stadtmauer, Marcela V. Maus, Wei-Ting Hwang, et al.


Conclusion: CTL019 manufacturing and administration post-ASCT is safe and feasible in patients with advanced MM. Correlation of PFS with CTL019 frequency in BM and prolonged PFS in 3 subjects is suggestive of clinical efficacy. A phase-two study of CTL019 using a 10-fold higher dose after first-line ASCT in high-risk MM patients is ongoing.

975

Philippe Moreau, Asher A. Chanan-Khan, Andrew W. Roberts, Amit B. Agarwal, et al.

Conclusions: VEN in combination with bortezomib and dexamethasone has an acceptable safety profile in patients with R/R MM. Efficacy results, including 68% ORR in all patients and 94% ORR in patients not refractory to bortezomib and who received 1 – 3 prior lines of therapy, indicates promising efficacy of this novel combination and supports the ongoing Phase 3 trial with this regimen in patients with R/R MM.

976

Irene M. Ghobrial, Ashraf Z Badros, James J. Vredenburgh, Jeffrey Matous, et al.


Conclusion:The combination of elotuzumab, lenalidomide, and dexamethasone is very well tolerated among patients with high-risk SMM. The high response rates among this patient population, who would otherwise remain untreated, is a promising starting point for the paradigm shift towards early therapeutic intervention in patients with high-risk SMM.

 
977

Nizar J. Bahlis, Rami Kotb, Michael Sebag, Heather J. Sutherland, et al.

Conclusions: Selinexor in combination with bortezomib and dex is well tolerated and highly active in refractory MM. Toxicities are manageable and similar to selinexor or bortezomib monotherapy. Peripheral neuropathy is uncommon, consistent with the use of weekly bortezomib sc and the lack of neuropathy with selinexor. Overall, the SdB regimens induced an ORR of 77% with ≥VGPR of 27%. In patients with PI-refractory MM, the ORR was 58%, indicating that the addition of selinexor restores sensitivity to bortezomib. These results confirm the preclinical data supporting synergistic effects of selinexor when combined with PIs. This promising, once-weekly treatment regimen may provide deeper and more durable responses in pts with relapsed / refractory MM, including those with PI-refractory disease.

978

Frank Bridoux, Brigitte Pegourie, Karine Augeul-Meunier, Bruno Royer, et al.


Conclusions: This randomized trial demonstrates that in MM patients with MCN and severe AKI treated with a bortezomib-based regimen, intensive HCO-HD results in higher renal recovery rate than HD with conventional high-flux dialyzers.